Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of an adjuvanted RSV vaccine in healthy older adults; trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection
• Respiratory Tract Infection

Drugs mentioned

• RSV vaccine, adjuvanted

Snippet

Sponsor: Pfizer | Conditions: Respiratory Tract Infection | Phase 2 | Status: TERMINATED | Results posted: 2021-08-26